Clinical-stage biotech company Sareum Holdings plc (AIM: SAR) on Monday announced positive topline results from its Phase 1a trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor aimed at treating autoimmune diseases.

The final cohort in the Multiple Ascending Dose stage showed that blood plasma levels of SDC-1801 significantly exceeded predicted therapeutic exposure, with a half-life of 17 to 20 hours, indicating potential for once-daily dosing. No deaths or serious adverse events were reported. Early data suggests no significant changes in blood cell counts or serum creatinine levels, common dose-limiting side effects in similar treatments.

Further unblinded data, including mild or moderate adverse events and biomarkers of TYK2 and/or JAK1 inhibition, is expected in Q3 2024.

Sareum, based in Cambridge, UK, focuses on developing kinase inhibitors for autoimmune diseases and cancer. Its lead candidate, SDC-1801, targets TYK2 and JAK1 and is in Phase 1 clinical development. Sareum is also advancing SDC-1802 for cancer immunotherapy.